{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+solution&page=16",
    "query": {
      "intervention": "Vehicle solution",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 454,
    "total_pages": 46,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+solution&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+solution&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T10:59:23.119Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05180500",
      "title": "Safety and Acceptability of Q GRFT Nasal Spray for COVID-19 Prophylaxis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19",
        "Pharmacokinetics",
        "Safety"
      ],
      "interventions": [
        {
          "name": "Q-Griffithsin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sharon Hillier",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 50,
      "start_date": "2022-03-15",
      "completion_date": "2022-12-07",
      "has_results": true,
      "last_update_posted_date": "2024-04-23",
      "last_synced_at": "2026-10-20T10:59:23.119Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05180500"
    },
    {
      "nct_id": "NCT04097730",
      "title": "Steroids and Cross-linking for Ulcer Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Keratitis Bacterial"
      ],
      "interventions": [
        {
          "name": "Moxifloxacin Ophthalmic",
          "type": "DRUG"
        },
        {
          "name": "Difluprednate Ophthalmic",
          "type": "DRUG"
        },
        {
          "name": "Riboflavin Ophthalmic",
          "type": "DRUG"
        },
        {
          "name": "Topical Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Thomas M. Lietman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 280,
      "start_date": "2020-09-24",
      "completion_date": "2024-09-18",
      "has_results": false,
      "last_update_posted_date": "2025-02-03",
      "last_synced_at": "2026-10-20T10:59:23.119Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Miami, Florida",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04097730"
    },
    {
      "nct_id": "NCT01302119",
      "title": "Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Onychomycosis of Toenails"
      ],
      "interventions": [
        {
          "name": "AN2690 Topical Solution, 5%",
          "type": "DRUG"
        },
        {
          "name": "Solution Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 604,
      "start_date": "2011-02",
      "completion_date": "2013-02-20",
      "has_results": true,
      "last_update_posted_date": "2019-04-03",
      "last_synced_at": "2026-10-20T10:59:23.119Z",
      "location_count": 26,
      "location_summary": "Phoenix, Arizona • Novato, California • Oceanside, California + 22 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Novato",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01302119"
    },
    {
      "nct_id": "NCT05403827",
      "title": "A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "K-161",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kowa Research Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 644,
      "start_date": "2022-07-03",
      "completion_date": "2023-12-05",
      "has_results": true,
      "last_update_posted_date": "2025-01-14",
      "last_synced_at": "2026-10-20T10:59:23.119Z",
      "location_count": 51,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 45 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Covina",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05403827"
    },
    {
      "nct_id": "NCT01703559",
      "title": "The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Night Vision Complaints",
        "Decrease in Night Vision",
        "Disturbance; Vision, Loss"
      ],
      "interventions": [
        {
          "name": "Phentolamine Mesylate Ophthalmic Solution 1.0%",
          "type": "DRUG"
        },
        {
          "name": "Phentolamine Mesylate Ophthalmic Solution 0.5%",
          "type": "DRUG"
        },
        {
          "name": "Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Opus Genetics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 60,
      "start_date": "2011-09-09",
      "completion_date": "2012-04-30",
      "has_results": true,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-20T10:59:23.119Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01703559"
    },
    {
      "nct_id": "NCT05133180",
      "title": "Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "Oxervate",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dompé Farmaceutici S.p.A",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2022-01-19",
      "completion_date": "2022-12-19",
      "has_results": true,
      "last_update_posted_date": "2024-06-07",
      "last_synced_at": "2026-10-20T10:59:23.119Z",
      "location_count": 7,
      "location_summary": "Glendale, California • Newport Beach, California • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05133180"
    },
    {
      "nct_id": "NCT05409235",
      "title": "Nesvategrast (OTT166) in Diabetic Retinopathy (DR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "OTT166",
          "type": "DRUG"
        },
        {
          "name": "Vehicle control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OcuTerra Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 225,
      "start_date": "2022-07-29",
      "completion_date": "2023-12-29",
      "has_results": true,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-10-20T10:59:23.119Z",
      "location_count": 67,
      "location_summary": "Peoria, Arizona • Phoenix, Arizona • Beverly Hills, California + 59 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05409235"
    },
    {
      "nct_id": "NCT02349516",
      "title": "Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Squalamine Lactate Ophthalmic Solution 0.2%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Starr Muscle",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2015-02",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2016-06-01",
      "last_synced_at": "2026-10-20T10:59:23.119Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02349516"
    },
    {
      "nct_id": "NCT04784091",
      "title": "Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Blepharitis"
      ],
      "interventions": [
        {
          "name": "TP-03",
          "type": "DRUG"
        },
        {
          "name": "TP-03 Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tarsus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 412,
      "start_date": "2021-04-29",
      "completion_date": "2022-05-09",
      "has_results": true,
      "last_update_posted_date": "2023-12-21",
      "last_synced_at": "2026-10-20T10:59:23.119Z",
      "location_count": 21,
      "location_summary": "Scottsdale, Arizona • Northridge, California • San Ramon, California + 18 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "San Ramon",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04784091"
    },
    {
      "nct_id": "NCT05451329",
      "title": "A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma, Open-Angle"
      ],
      "interventions": [
        {
          "name": "VVN539 Ophthalmic Solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "VVN539 Ophthalmic Solution 0.04%",
          "type": "DRUG"
        },
        {
          "name": "VVN539 Ophthalmic Solution Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VivaVision Biotech, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2022-07-12",
      "completion_date": "2022-12-22",
      "has_results": true,
      "last_update_posted_date": "2024-01-17",
      "last_synced_at": "2026-10-20T10:59:23.119Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05451329"
    }
  ]
}